NLRP3 and gout: Accordingly, microtubule-destabilizing agents, such as colchicine (Gigant et al., 2009), suppress the activation of NLRP3 inflammasome both in vitro and in vivo (Martinon et al., 2006; Dalbeth et al., 2014), which may explain the underlying mechanism for colchicine’s application in the treatment of NLRP3 activation related diseases such as gout and familial Mediterranean fever (Kiraz et al., 1998; Martinon et al., 2006).